Celldex Therapeutics, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging -0.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.04 | $-0.94 | +9.6% | Beat | |
| Q1 FY26 | $-1.10 | $-1.18 | -7.3% | Miss | |
| Q4 FY25 | not reported | $-1.22 | not reported | not reported | |
| Q3 FY25 | $-0.88 | $-1.01 | -14.8% | Miss | |
| Q2 FY25 | $-0.86 | $-0.85 | +1.2% | Beat | |
| Q1 FY25 | $-0.75 | $-0.81 | -8.0% | Miss | |
| Q4 FY24 | $-0.75 | $-0.71 | +5.3% | Beat | |
| Q3 FY24 | $-0.69 | $-0.64 | +7.3% | Beat | |
| Q2 FY24 | $-0.59 | $-0.54 | +8.5% | Beat | |
| Q1 FY24 | $-0.67 | $-0.56 | +16.4% | Beat | |
| Q4 FY23 | $-0.76 | $-0.57 | +25.0% | Beat | |
| Q3 FY23 | $-0.67 | $-0.81 | -20.9% | Miss |
Back to CLDX overview · CLDX holders · CLDX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.